Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EDP-322 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Intervention | EXPERIMENTAL | EDP-322 v. Placebo |
| Name | Type | Description |
|---|---|---|
| EDP-322 | DRUG | - |
Inclusion Criteria: * Healthy adult males or females between 18 and 45 years of age * Females are eligible if documentation exists that they are surgically sterilized * In good general health \[determined by medical history, physical examination, clinical laboratory tests, and without evidence of a...
EDP-322 is an investigational small molecule being developed for the treatment of skin and soft tissue infections (SSTI), including those caused by methicillin-resistant Staphylococcus aureus (MRSA). It is currently in Phase 1 clinical development and has not been approved by the FDA.
EDP-322 is being developed by Enanta Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker ENTA. The drug is in Phase 1 clinical development for infectious disease indications.
EDP-322 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Clinical trials have been completed in healthy volunteers to evaluate safety and pharmacokinetics.
EDP-322 has been studied in two completed Phase 1 trials. NCT00989872 evaluated ascending single oral doses in healthy volunteers, and NCT00990145 was a multiple ascending-dose study. Both trials were conducted in the United States and enrolled healthy adults.
Yes, EDP-322 is also referred to as EDP 322 in clinical trial records. Both names refer to the same investigational small molecule being developed by Enanta Pharmaceuticals for skin and soft tissue infections, including MRSA.